MEDLINE Journals

    Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.

    Authors
    Kierkus J, Furmaga-Jablonska W, Sullivan JE, et al. 
    Institution

    Department of Gastroenterology, Hepatology and Immunology, The Children's Memorial Health Institute, Warsaw, Poland. j.kierkus@med-net.pl

    Source
    Dig Dis Sci 2011 Feb; 56(2) :425-34.
    Abstract

    Limited data on proton pump inhibitors in infants led regulatory agencies to request sponsors to conduct pediatric studies.To determine the pharmacodynamic response to pantoprazole in infants with GERD to aid the dose selection for an efficacy study.In two open-label studies, neonates and preterm infants (study 1, ~1.2 mg/kg [high dose]) and infants 1 through 11 months (study 2, ~0.6 [low dose] or ~1.2 mg/kg [high dose]) received once-daily pantoprazole. Twenty-four-hour dual-electrode pH-metry parameters were compared between predose and steady state (≥5 days) (two-sided paired t test). Treatment was administered for ≤6 weeks.In studies 1 and 2, 21 and 24 patients, respectively, were enrolled for pharmacodynamic evaluation. The high dose provided similar responses in the two studies and improved these parameters significantly: mean gastric pH and percent time gastric pH > 4 increased (p < 0.05 both studies), normalized area under the curve (AUC) of gastric H(+) activity decreased (p < 0.05 study 2), and normalized AUC of esophageal H(+) activity decreased (p < 0.05 both studies). The AUC of esophageal pH < 4 decreased. Normalized AUC of esophageal H(+) activity decreased (p < 0.05 both studies), indicating refluxate pH increased, although this was not reflected in any change in mean esophageal pH or reflux index. The normalized AUC of esophageal H(+) activity was a more sensitive measure of changes in esophageal pH.In neonates, preterm infants, and infants aged 1 through 11 months, pantoprazole (high dose) improved pH-metry parameters after ≥5 consecutive daily doses, and was generally well tolerated for ≤6 weeks.

    Mesh
    2-Pyridinylmethylsulfinylbenzimidazoles
    Anti-Ulcer Agents
    Dose-Response Relationship, Drug
    Female
    Gastroesophageal Reflux
    Humans
    Hydrogen-Ion Concentration
    Infant
    Infant, Newborn
    Infant, Premature
    Infant, Premature, Diseases
    Male
    Language

    eng

    Pub Type(s)
    Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
    PubMed ID

    20607405

    Content Manager
    Related Content

    Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.

    Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).

    Age-dependent pharmacokinetics of lansoprazole in neonates and infants.

    Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.

    Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.

    Cisapride decreases gastroesophageal reflux in preterm infants.

    Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER).

    Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.